信必可都保80ug4.5ug吸入联合无水缓释茶碱片口服与信必可都保160ug4.5ug吸入治疗成人支气管哮喘疗效对比-comparison of curative effect between xinbizuobao 80 ug 4.5 ug inhalation combined with anhydrous sustained-release theophylline tablets and xinbizuobao 160 ug 4.5.docxVIP

信必可都保80ug/4.5ug吸入联合无水缓释茶碱片口服与信必可都保160ug/4.5ug吸入治疗成人支气管哮喘疗效对比硕士研究生：陈瑞芳导师：张挪富教授中文摘要目的：观察布地奈德／福莫特罗干粉吸入剂(商品名信必可都保)80ug/4.5ug（80ug／4.5ug／喷）联合口服无水茶碱缓释片(商品名舒弗美)和单用信必可都保160ug/4.5ug（160ug／4.5ug／喷）治疗中度成人支气管哮喘的疗效和安全性及药物经济学。方法：60例中度哮喘患者采用开放随机对照的方法分成两组，A组30例，B组30例。A组：给予信必可都保80ug/4.5ug（布地奈德／福莫特罗联合干粉吸入剂，80ug／4.5ug／喷），每日早、晚各1次吸入治疗联合无水缓释茶碱片(舒弗美)0.2g每12h一次口服治疗；B组，给予信必可都保160ug/4.5ug（布地奈德／福莫特罗联合干粉吸入剂，160ug／4.5ug／喷），每日早、晚各1次吸入治疗。疗程12周。信必可都保不适时可按需使用。观察治疗前后两组的临床症状和FEV1、FEV1％的改变及药物不良反应。结果：治疗前后A、B两组的临床基本控制率、ACT评分、第1秒用力呼气容积(FEV1)和FEV1占预计值的百分比（FEV1％）相比较差异有显著的统计学意义(P0.01),而两组间比较差异无统计学意义(P0.05)。两组不良事件的发生率无差别(P0.05)。A组3个月人均药物治疗费用更低。结论：吸入信必可都保（80ug／4.5ug／喷）联合口服无水茶碱缓释片(舒弗美)和单用吸入信必可都保（160ug／4.5ug／喷）治疗中度成人支气管哮喘有相近的疗效,副作用轻,具有良好的依从性，前者显示更好的药物经济学。【关键词】布地奈德／福莫特罗干粉吸入剂；舒弗美；联合治疗；支气管哮喘TheComparisonofEffectofSymbicortTurbuhaler80ug/4.5ugcombinedwithAnhydrousTheophyllineSustainedTabletsandSymbicortTurbuhaler160ug/4.5ugintheTreatmentofPatientswithModerateBronchialAsthmaPostgraduate:RuifangChenSpeciality:InternalMedicineTutor:Prof.ZhangNuofuABSTRACTObjective:Toobservetheefficacy，safetyandpharmacoeconomicsofinhaledSymbicortturbuhaler(budesonideandformoterolfumaratepowder)80ug/4.5ugcombinedwithoralAnhydrousTheophyllineSustainedtabletsandinhaledSymbicortTurbuhaler160ug/4.5uginthetreatmentofpatientswithmoderatebronchialasthmaandcomparethecurativeeffect.Methods:60patientswithmoderatebronchialasthmawererandomlydividedintoAandBgroups.30casesingroupAweretreatedwithinhaledSymbicortturbuhaler80ug/4.5ug,oneinhalations，twiceadaycombinedwithoralsustained-releasetheophylline,200mgper12hour.30casesingroupBweretreatedwithinhaledSymbicortturbuhaler160ug/4.5ug,oneinhalations，twiceaday.Bothgroupswerereceivedatreatmentcourseof12weeks.Furthermore，Symbicortturbuhalercouldbeusedwhensymptomswerepoorlycontrolled.Thechangeofclinicalsymptoms、FEVl、FEVl％andadverseeventswereobservedbeforeandaftertreatment.Results:Bothgroupsgotremarkableimprovementinclinicbasiccontrolrate,ACTscoresandlungfunction(FEVlandFEVl％)andtheyshowsignificantdifference